To this end, FLT3 mutations are found in roughly 30% of acute myeloid leukemia (AML) cases and, to a lesser extent, in acute lymphoblastic leukemia (ALL), making it an important therapeutic target [1,2]. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.